C2 PHARMA, a global manufacturer and supplier of ophthalmic and niche active pharmaceutical ingredients (APIs), is expanding global access to its portfolio of APIs with new regulatory submissions and approvals. Earlier this year, the company received a CEP for Cyclopentolate Hydrochloride and recently a C-DMF for Digoxin, supporting its position in ophthalmic and niche APIs. 
 
Along with the C-DMF and CEP approvals, the most recent submissions include:
 
o   Brimonidine Tartrate
o   CADIFA under submission
o   Bitmatoprost
o   Canadian-DMF under submission
o   Pilocarpine Hydrochloride Micronized
o   Korean K-DMF under submission
o   Tropicamide
o   China C-DMF under submission
 
A full list of products and their filings can be found here, with the R&D pipeline available here. With the expansion of its portfolio of Ophthalmic APIs, C2 PHARMA has signed an agreement with an additional CMO partner, SMS Lifesciences to strengthen its manufacturing network and accelerates its R&D portfolio of Ophthalmic products to the commercial market. 

“We believe in forging long-term relationships with organizations that share our passion for quality, reliability, and excellence,” said Dr. James Lawler, General Manager of C2 PHARMA. “With the addition of SMS Lifesciences to our CMO network, we are confident in our ability to deliver exceptional pharmaceutical ingredients with the best cost-to-quality to meet the healthcare needs of patients worldwide.”
 
The company will be exhibiting at CPhI Worldwide 2023 in Barcelona in Hall 4, Booth D49